Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: An effect of improved systemic therapy?

C. Lin, S. Turner, H. Gurney, A. Peduto

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Metastases from prostate cancer occur largely in bone through a haematogenous route. Metastatic spread of prostate cancer to the leptomeninges was rarely seen in the past. However, there has been a recent increase in presentations of leptomeningeal spread from prostate cancer in our institutions. Between 2004 and 2006, four patients were diagnosed with metastatic prostate cancer with leptomeningeal metastases in our centres. All four patients had hormone refractory prostate cancer and had previously had chemotherapy. The median survival of these patients was approximately 15 months from the time of hormone refractoriness. The prognosis of leptomeningeal metastasis secondary to metastatic prostate cancer is poor, ranging from 2 to 7 months as seen in our series. New cases of leptomeningeal metastases seen in our series are hypothesized to be secondary to the use of effective modern systemic treatments. A parallel might be drawn with the increased rate of central nervous system metastases in breast cancer since the introduction of effective cytotoxic treatments and more recently targeted therapies. We suggest the clinicians to be aware of the potential change of natural history and pattern of progression in metastatic prostate cancer.

LanguageEnglish
Pages376-381
Number of pages6
JournalJournal of Medical Imaging and Radiation Oncology
Volume52
Issue number4
DOIs
Publication statusPublished - Aug 2008
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Hormones
Neoplasm Metastasis
Therapeutics
Natural History
Central Nervous System
Breast Neoplasms
Bone and Bones
Drug Therapy
Survival

Cite this

@article{0dd5240eb0c54b2b81b08fd213223504,
title = "Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: An effect of improved systemic therapy?",
abstract = "Metastases from prostate cancer occur largely in bone through a haematogenous route. Metastatic spread of prostate cancer to the leptomeninges was rarely seen in the past. However, there has been a recent increase in presentations of leptomeningeal spread from prostate cancer in our institutions. Between 2004 and 2006, four patients were diagnosed with metastatic prostate cancer with leptomeningeal metastases in our centres. All four patients had hormone refractory prostate cancer and had previously had chemotherapy. The median survival of these patients was approximately 15 months from the time of hormone refractoriness. The prognosis of leptomeningeal metastasis secondary to metastatic prostate cancer is poor, ranging from 2 to 7 months as seen in our series. New cases of leptomeningeal metastases seen in our series are hypothesized to be secondary to the use of effective modern systemic treatments. A parallel might be drawn with the increased rate of central nervous system metastases in breast cancer since the introduction of effective cytotoxic treatments and more recently targeted therapies. We suggest the clinicians to be aware of the potential change of natural history and pattern of progression in metastatic prostate cancer.",
author = "C. Lin and S. Turner and H. Gurney and A. Peduto",
year = "2008",
month = "8",
doi = "10.1111/j.1440-1673.2008.01973.x",
language = "English",
volume = "52",
pages = "376--381",
journal = "Journal of Medical Imaging and Radiation Oncology",
issn = "1754-9477",
publisher = "Wiley-Blackwell, Wiley",
number = "4",

}

Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer : An effect of improved systemic therapy? / Lin, C.; Turner, S.; Gurney, H.; Peduto, A.

In: Journal of Medical Imaging and Radiation Oncology, Vol. 52, No. 4, 08.2008, p. 376-381.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer

T2 - Journal of Medical Imaging and Radiation Oncology

AU - Lin, C.

AU - Turner, S.

AU - Gurney, H.

AU - Peduto, A.

PY - 2008/8

Y1 - 2008/8

N2 - Metastases from prostate cancer occur largely in bone through a haematogenous route. Metastatic spread of prostate cancer to the leptomeninges was rarely seen in the past. However, there has been a recent increase in presentations of leptomeningeal spread from prostate cancer in our institutions. Between 2004 and 2006, four patients were diagnosed with metastatic prostate cancer with leptomeningeal metastases in our centres. All four patients had hormone refractory prostate cancer and had previously had chemotherapy. The median survival of these patients was approximately 15 months from the time of hormone refractoriness. The prognosis of leptomeningeal metastasis secondary to metastatic prostate cancer is poor, ranging from 2 to 7 months as seen in our series. New cases of leptomeningeal metastases seen in our series are hypothesized to be secondary to the use of effective modern systemic treatments. A parallel might be drawn with the increased rate of central nervous system metastases in breast cancer since the introduction of effective cytotoxic treatments and more recently targeted therapies. We suggest the clinicians to be aware of the potential change of natural history and pattern of progression in metastatic prostate cancer.

AB - Metastases from prostate cancer occur largely in bone through a haematogenous route. Metastatic spread of prostate cancer to the leptomeninges was rarely seen in the past. However, there has been a recent increase in presentations of leptomeningeal spread from prostate cancer in our institutions. Between 2004 and 2006, four patients were diagnosed with metastatic prostate cancer with leptomeningeal metastases in our centres. All four patients had hormone refractory prostate cancer and had previously had chemotherapy. The median survival of these patients was approximately 15 months from the time of hormone refractoriness. The prognosis of leptomeningeal metastasis secondary to metastatic prostate cancer is poor, ranging from 2 to 7 months as seen in our series. New cases of leptomeningeal metastases seen in our series are hypothesized to be secondary to the use of effective modern systemic treatments. A parallel might be drawn with the increased rate of central nervous system metastases in breast cancer since the introduction of effective cytotoxic treatments and more recently targeted therapies. We suggest the clinicians to be aware of the potential change of natural history and pattern of progression in metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=52049098699&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1673.2008.01973.x

DO - 10.1111/j.1440-1673.2008.01973.x

M3 - Article

VL - 52

SP - 376

EP - 381

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

SN - 1754-9477

IS - 4

ER -